Altimmune price target lowered to $12 from $15 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Altimmune to $12 from $15 and keeps a Buy rating on the shares. The firm says the company’s MOMENTUM data demonstrated pemvidutide’s differentiation in obesity. The analyst continues to view pemvidutide as a “potentially differentiated therapeutic candidate with best-in-class potential” in both obesity and metabolic dysfunction-associated steatohepatitis compared to other GLP-1 agonist drugs. The target drop reflects the removal of estimated revenues associated with HepTcell to reflect the discontinuation of the program.